David A. Siegel Bio Atla, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCAB
# of Institutions
42Shares Held
13.5MCall Options Held
20.7KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.84MShares$3.29 Million1.25% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.78MShares$1.21 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.49MShares$1.01 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.37MShares$934,3710.03% of portfolio
-
Black Rock Inc. New York, NY792KShares$538,2600.0% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $24.7M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...